Cargando…

Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4(+) T-cell response with pre-primed responses directed against common cold coronaviruses

INTRODUCTION: The nonstructural protein 12 (NSP12) of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has a high sequence identity with common cold coronaviruses (CCC). METHODS: Here, we comprehensively assessed the breadth and specificity of the NSP12-specific T-cell response...

Descripción completa

Detalles Bibliográficos
Autores principales: Westphal, Tim, Mader, Maria, Karsten, Hendrik, Cords, Leon, Knapp, Maximilian, Schulte, Sophia, Hermanussen, Lennart, Peine, Sven, Ditt, Vanessa, Grifoni, Alba, Addo, Marylyn Martina, Huber, Samuel, Sette, Alessandro, Lütgehetmann, Marc, Pischke, Sven, Kwok, William W., Sidney, John, Schulze zur Wiesch, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196118/
https://www.ncbi.nlm.nih.gov/pubmed/37215095
http://dx.doi.org/10.3389/fimmu.2023.1182504
Descripción
Sumario:INTRODUCTION: The nonstructural protein 12 (NSP12) of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has a high sequence identity with common cold coronaviruses (CCC). METHODS: Here, we comprehensively assessed the breadth and specificity of the NSP12-specific T-cell response after in vitro T-cell expansion with 185 overlapping 15-mer peptides covering the entire SARS-CoV-2 NSP12 at single-peptide resolution in a cohort of 27 coronavirus disease 2019 (COVID-19) patients. Samples of nine uninfected seronegative individuals, as well as five pre-pandemic controls, were also examined to assess potential cross-reactivity with CCCs. RESULTS: Surprisingly, there was a comparable breadth of individual NSP12 peptide-specific CD4(+) T-cell responses between COVID-19 patients (mean: 12.82 responses; range: 0–25) and seronegative controls including pre-pandemic samples (mean: 12.71 responses; range: 0–21). However, the NSP12-specific T-cell responses detected in acute COVID-19 patients were on average of a higher magnitude. The most frequently detected CD4(+) T-cell peptide specificities in COVID-19 patients were aa236–250 (37%) and aa246–260 (44%), whereas the peptide specificities aa686–700 (50%) and aa741–755 (36%), were the most frequently detected in seronegative controls. In CCC-specific peptide-expanded T-cell cultures of seronegative individuals, the corresponding SARS-CoV-2 NSP12 peptide specificities also elicited responses in vitro. However, the NSP12 peptide-specific CD4(+) T-cell response repertoire only partially overlapped in patients analyzed longitudinally before and after a SARS-CoV-2 infection. DISCUSSION: The results of the current study indicate the presence of pre-primed, cross-reactive CCC-specific T-cell responses targeting conserved regions of SARS-CoV-2, but they also underline the complexity of the analysis and the limited understanding of the role of the SARS-CoV-2 specific T-cell response and cross-reactivity with the CCCs.